Chiasma, Inc. (NASDAQ:CHMA) $CHMA #Stocks #Pharmaceuticals Worth a Look
Chiasma is a clinical, late-stage biopharmaceutical company
Today the FDA is also expected to rule on Chiasma Inc’s (NASDAQ: CHMA) NDA for Mycapssa, which is being evaluated as a maintenance therapy for acromegaly.
Chiasma, Inc. is a biopharmaceutical company.
The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection.
Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies.
The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.
The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day.
The Company’s TPE technology enhances the absorption through the intestinal wall of drugs.
The Company also focuses on developing CH2 for Orphan indication.
Shayne Heffernan Trade Idea
“If the FDA approve NDA for Mycapssa, our current price target of Chiasma will come in around $12.40 giving the stock a price increase of +88.74%.”
Overall, the bias in prices is: Upwards.
Note: this chart shows extraordinary price action to the upside.
The projected upper bound is: 7.29.
The projected lower bound is: 5.95.
The projected closing price is: 6.62.
A black body occurred (because prices closed lower than they opened).
During the past 10 bars, there have been 5 white candles and 5 black candles. During the past 50 bars, there have been 25 white candles and 25 black candles.
Three black candles occurred in the last three days. Although these candles were not big enough to create three black crows, the steady downward pattern is bearish.
Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.
One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 41.3584. This is not an overbought or oversold reading. The last signal was a sell 2 period(s) ago.
Relative Strength Index (RSI)
The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 55.09. This is not a topping or bottoming area. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a sell 22 period(s) ago.
Commodity Channel Index (CCI)
The CCI shows overbought (above 100) and oversold (below -100) areas. The current value of the CCI is 9. This is not a topping or bottoming area. The last signal was a sell 1 period(s) ago.
The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a buy 4 period(s) ago.
Rex Takasugi – TD Profile
CHIASMA INC closed down -0.210 at 6.570. Volume was 235% above average (trending) and Bollinger Bands were 18% narrower than normal.
Open High Low Close Volume 6.800 6.840 6.350 6.570 1,304,488
Technical Outlook Short Term: Neutral Intermediate Term: Bullish Long Term: Bullish
Moving Averages: 10-period 50-period 200-period Close: 6.66 5.84 5.06 Volatility: 58 75 78 Volume: 615,194 391,116 329,609
Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.
CHIASMA INC is currently 29.8% above its 200-period moving average and is in an upward trend. Volatility is relatively normal as compared to the average volatility over the last 10 periods.
Our volume indicators reflect volume flowing into and out of CHMA.O at a relatively equal pace (neutral). Our trend forecasting oscillators are currently bullish on CHMA.O and have had this outlook for the last 4 periods.